Piper Jaffray Upgrades Horizon Pharma To Overweight

Analysts at Piper Jaffray upgraded Horizon Pharma plc HZNP from Neutral to Overweight. The price target for Horizon Pharma has been raised from $21.00 to $31.00. Horizon Pharma shares have gained 60.42% over the past 52 weeks, while the S&P 500 index has surged 11.42% in the same period. Horizon Pharma's shares rose 2.02% to $26.30 in pre-market trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: UpgradesAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!